Possibilities of formoterol to enhanced the peripheral lung deposition of the inhaled liposome corticosteroids

Respiratory Medicine

Volumn 96, Issue 12, 2002, Pages 999-1005

  Saari, S M ^a   Vidgren, M T ^b   Herrala, J ^a   Turjanmaa, V M H ^a   Koskinen, M O ^a   Nieminen, M M ^c  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Deposition; Formoterol; Inhaled corticosteroids; Liposome

Indexed keywords

AMINOPHYLLINE; ANTIINFLAMMATORY AGENT; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; DILAUROYLPHOSPHATIDYLCHOLINE; FORMOTEROL; LIPOSOME; SALBUTAMOL; TECHNETIUM 99M; TERBUTALINE; BECLOMETASONE; DIAGNOSTIC AGENT; ETHANOLAMINE DERIVATIVE; GLUCOCORTICOID; TECHNETIUM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RESPONSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; ISOTOPE LABELING; LUNG FUNCTION TEST; LUNG SCINTISCANNING; MALE; NEBULIZER; PRIORITY JOURNAL; SPIROMETRY; CLINICAL TRIAL; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; MUCOCILIARY CLEARANCE; PATHOPHYSIOLOGY; SCINTISCANNING; TIME;

ADMINISTRATION, INHALATION; ADULT; AGED; AREA UNDER CURVE; ASTHMA; BECLOMETHASONE; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; GLUCOCORTICOIDS; HUMANS; LIPOSOMES; LUNG; MALE; MIDDLE AGED; MUCOCILIARY CLEARANCE; RESPIRATORY FUNCTION TESTS; TECHNETIUM; TIME FACTORS;

EID: 0036892679     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2002.1393     Document Type: Article

References (39)

1. Seberova E, Andersson A. Oxis (formoterol given by Turbuhaler) showed as rapid an action as salbutamol given by a pMDI. Respir Med 2000; 94: 607-611.
2. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10: 2484-2489.
3. Derom EY, Pauwels RA. Time course of bronchodilating effect of inhaled formoterol, a potent and long-acting sympatomimetic. Thorax 1992; 47: 30-33.
4. Schreurs AJM, Sinnighe Damste HEJ, de Graaff CS, Greefhorst APM. A dose-response study with formoterol Turbuhaler as maintenance therapy in asthmatic patients. Eur Respir J 1996; 9: 1678-1683.
5. Kesten S, Chapman KR, Broder I, Cartier A, Hyland RH, Knight A. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am Rev Respir Dis 1991; 144 (Pt 1): 622-625.
6. 99mTc-labelled beclomethasone-DLPC liposomes in mild and severe asthma. Chest 1998; 113: 1573-1579.
7. Saari SM, Vidgren MT, Koskinen MO, Turjanmaa VMH, Nieminen MM. Pulmonary distribution and clearance of two beclomethasone liposome formulations in healthy volunteers. Int J Pharm 1999; 181: 1-9.
8. Chung KF, Jeyasingh K, Snashall PD. Influence of airway calibre on the intrapulmonary dose and distribution of inhaled aerosol in normal and asthmatic subjects. Eur Respir J 1988; 1: 890-895.
9. Pauwels RA, Löfdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-1411.
10. Global Initiative for Asthma. Pocket Guide for Asthma Management And Prevention. Washington: National Heart, Lung and Blood Institute, 1998.
11. Dahl R, Bjemer L. Nordic consensus report on asthma management. Respir Med 2000; 94: 299-327.
12. Waldrep JC, Scherer PW, Hess GD, Black MB, Knight BN. Nebulized glucocorticoids in liposomes: aerosol characteristics and human dose estimates.J Aerosol Med 1994; 7: 135-144.
13. Nieminen MM, Holli H, Lahdensuo A, Muittari A, Karvonen J. Aerosol deposition in automatic dosimeter nebulization. Eur J Respir Dis 1987; 71: 145-152.
14. Nieminen MM, Lahdensuo A, Kellomäki L, Karvonen J, Muittari A. Methacholine bronchial challenge using dosimeter with controlled tidal breathing. Thorax 1988; 43: 896-900.
15. Nieminen MM, Moilanen E, Nyholm J-E, et al. Platelet-activating factor impairs tracheobronchial transport and increases plasma leukotriene. Eur Respir J 1991; 4: 561-570.
16. Smaldone GC, Perry RJ, Bennett WD, Messina MS, Swang J, Ilowite J. Interpretation of '24 hour lung retention' in studies of mucociliary clearance. J Aerosol Med 1988; 1: 11-20.
17. Smaldone GC, Walser L, Perry RJ, Ilowite JS, Bennett WD, Greco M. Generation and administration of aerosols for medical and physiological studies. J Aerosol Med 1989; 2: 81-87.
18. Macey DJ, Marshall R. Absolute quantitation of radiotracer uptake in the lungs using gamma camera. J Nucl Med 1982; 23: 731-735.
19. Van As A. The role of selective beta 2-adrenoreceptor stimulants in the control of ciliary activity. Respiration 1974; 31: 146-151.
20. Iravani J, Melville GN. Mucociliary function of the respiratory as influenced by drugs. Respiration 1974; 31: 350-357.
21. Phipps RJ. Adrenergic stimulation of mucus secretion in the human bronchus. J Physiol 1979; 296: 44.
22. Hybbinette JC, Mercke U. Effects of sympathomimetic agonist and antagonist on mucociliary activity. Acta Otolaryngol 1982; 94: 121-130.
23. Sackner MA, Epstein S, Wanner A. Effect of beta-adrenergic agonists aerosolised by freon propellant on tracheal mucous velocity and cardiac output. Chest 1976; 69: 593-598.
24. 2-agonists and corticosteroids. Eur Respir J 2002; 19: 182-191.
25. Akpinarli A, Tuncer A, Saraclar Y, Sekerel BE, Kalayci O. Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trial. Arch Dis Child 1999; 81: 45-48.
26. Lötvall J, Mellen A, Arvidsson P, et al. Similar bronchodilation with formoterol delivered by Aerolizer or Turbuhaler. Can Respir J 1999; 6: 412-416.
27. Isawa T, Teshima T, Hirano T, Ebina A, Anazawa Y, Konno K. Effect of bronchodilation on the deposition and clearance of radioaerosol in bronchial asthma in remission. J Nucl Med 1987; 28: 1901-1906.
28. Borgström L, Derom E, Ståhl E, Wåhlin-Boll E, Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996; 53: 1636-1640.
29. Bateman JRM, Pavia D, Sheahan NF, Agnew JE, Clarce SW. Impaired tracheobronchial clearance in patients with mild stable asthma. Thorax 1983; 38: 463-467.
30. Pavia D, Bateman JRM, Shehan NF, Agnew JE, Clarke SW. Tracheobronchial mucociliary clearance in asthma: impairment during remission. Thorax 1985; 40: 171-175.
31. Messina MS, O'Riordan TG, Smaldone GC. Changes in mucociliary clearance during acute exacerbation of asthma. Am Rev Respir Dis 1991; 143: 993-997.
32. O'Riordan TG, Zwang J, Smaldone GC. Mucociliary clearance in adult asthma. Am Rev Respir Dis 1992; 146: 598-603.
33. 2-adrenoceptor agonist, on mucociliary activity. Eur J Pharm 1995; 285: 275-280.
34. Yates DB, Aspin N, Levison H, Jones MT, Bryan AC. Mucociliary tracheal transport in man. J Appl Physiol 1976; 39: 487-495.
35. Foster WM, Bergofsky EH, Bohning DE, et al. Effect of adrenergic agents and their mode of action on mucociliary clearance in man. J Appl Physiol 1976; 41: 146-152.
36. Sackner MA. Effect of respiratory drugs on mucociliary clearance. Chest 1978; 6: 958-966.
37. Melloni B, Germouty J. Influence sur la fonction muco-ciliare d'un nouveau beta-agoniste: formoterol Rev Mal Resp 1992; 9: 503-507.
38. Isawa T, Teshima T, Hirano T, Ebina A, Konno K. Effect of oral salbutamol on mucociliary clearance mechanisms in the lung. Tohoku J Exp Med 1986; 150: 51-61.
39. Agnew JE, Bateman JRM, Pavia D, Clarke SW. Peripheral airways mucus clearance in stable asthma is improved by oral corticosteroids therapy. Bull Eur Physiopathol Respir 1984; 20: 295-301.